Loading...

IRON DISC MEDICINE INC US FDA Inspections 8-K Filing

DSC

RN

DISC MEDICINE INC

(IRON)

2025 8-K

Show Summary

Summary

Financial Statements

Financial Statements

Financial Results

FDA Meeting Update

Operational Update

Conference Call

Stock Offering Agreement

Financial Results

Clinical Trial Update

Financial Results

Annual Meeting of Stockholders

Underwriting Agreement

Clinical Trial Updates

Financial Results Announcement

Product Launches

Financial Results Announcement

Appointment of CFO and COO

Phase 2 BEACON Study Data R...

Phase 1b/2 Study Results

Agreement with Jefferies LLC

Financial Results Announcement

ASH Annual Meeting and Expo...

Departure of CFO

Open Market Sale Agreement

Termination of Sales Agreement

Financial Results Announcement

Public Offering

Suspended Offering

Annual Meeting of Stockholders

Initial Data from Phase 2 T...

Earnings Reports

Resignation of Director

Financial Results and Corpo...

Securities Purchase Agreement

Sales Agreement with SVB Se...

Entry into a Material Defin...

External Links:

Disc Medicine, Inc. received positive feedback from the FDA regarding the design of its APOLLO trial for bitopertin in treating erythropoietic protoporphyria and X-linked protoporphyria, with plans to start the trial by mid-2025 and submit a New Drug Application in the second half of 2025.

AI Assistant

DISC MEDICINE INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.